Lipoprotein (a) in an urban population of Venezuela: Evidence that estrogenic deprivation increase in lipoprotein (A) levels is transitory;Lipoproteína (a) en una población urbana de Venezuela: Evidencia de que su incremento por deprivación estrogénica es transitorio

Anales de Medicina Interna

Volumn 24, Issue 7, 2007, Pages 324-327

  Bermúdez Pirela, Valmore ^a   Cabrera De Bravo, M ^a   Mengual Moreno, E ^a   Cano Ponce, C ^a   Leal Gonzalez E ^a   Lemus Antepaz, M ^a   Amell De Diaz A ^a   Sorell Gomez L ^a  

^a NONE

Author keywords

Apo (a); Hormonal replacement therapy; Lipoprotein (a); Risk factor; Tissue plasminogen activator

Indexed keywords

ESTROGEN; LIPOPROTEIN A;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; POPULATION RESEARCH; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX DIFFERENCE; THERAPY EFFECT; TREATMENT RESPONSE; URBAN POPULATION; VEIN PUNCTURE;

ADULT; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; TIME FACTORS; URBAN POPULATION; VENEZUELA;

EID: 38549139565     PISSN: 02127199     EISSN: 02127199     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Berg K. Lp (a) lipoprotein: An overview. Chemist and Physics of lipids 1994; 67: 9-16.
2. Enríquez L, Matas P: Lipoproteína (a): Fisiología y Consideraciones Clínicas y Terapéuticas. Med Clin (Barc) 2001; 116: 746-9.
3. Sorell L, Rojas G, Rodríguez M. A Sandwich ELISA based on anti-Apo(a) and anti Apo-B monoclonal antibodies for lipoprotein(a) measurement. Clinical Chemical Acta 1995; 236: 59-70.
4. Graninger D, Kirschenlohr H. Proliferation of human smooth muscle cells promoted by Lp (a). Science 1993; 260: 1655-58.
5. Kojima S, Harpel P, Rifkin D. Lipoprotein(a) Inhibits the Generation of Transforming Growth Factor b: An Endogenus inhibitor of Smooth Muscle Cell Migration. Journal of Cell Biology 1991; 113: 1439-45
6. Hancock MA, Boffa MB, Marcovina SM, Nesheim ME, Koschinsky, ML. Inhibition of plasminogen activation by lipoprotein (a): Critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem 2003; 278: 23260-69.
7. Evans R, Bunker K, Ukoli F, Küller L. Lipoprotein (a) distribution in a Nigeria Population. Ethn Healt 1997; 2: 47-58.
8. Jenner J, Ordovas J, Lamon S, Schaefer M, Wilson P, Castelli W, et al. Effects of age, sex, and menopausal status on plasma lipopreotein (a) levels. The Framingham offdpring Study. Circulation 1993; 87: 1135-41.
9. Kiran H; Kiran G; Ekerbicer HC, Kilinc M. Effects of intranasal estradiol treatment on serum lipoprotein (a) and lipids in hysterectomized women. Gynecol Obstet Invest 2004; 57: 191-5.
10. Soma M, Meschia M, Bruchi F, Morrisett J, Paoletti R, Fumagalli R, et al. Homonal agents used in lowering lipoprotein (a). Chemistry Physic Lipids 1994; 67: 345-50.